High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment

Journal of Crohn's and Colitis

Volumn 8, Issue 2, 2014, Pages 129-136

  Magro, Fernando ^a,b,c   Rodrigues Pinto, Eduardo ^a   Santos Antunes, João ^a,b   Vilas Boas, Filipe ^a   Lopes, Susana ^a   Nunes, Amadeu ^a   Camila Dias, Claudia ^b   Macedo, Guilherme ^a  

^a Centro Hospitalar Universitário de São João   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

C reactive protein; Crohn disease; Infliximab; Prognosis; Treatment outcome

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG INDICATION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIMARY NONRESPONSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPONSE AFTER THERAPEUTIC ADJUSTMENT; RETROSPECTIVE STUDY; SUSTAINED RESPONSE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

C-REACTIVE PROTEIN; CROHN DISEASE; INFLIXIMAB; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 84892844317     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.07.005     Document Type: Article

References (44)

1. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease - 2 volume set, 9th ed.
2. Lashner B. Inflammatory bowel disease. Cleveland Clinic: Current Clinical Medicine - 2009 2009, Saunders, Philadelphia, Pa. W.D. Carey (Ed.).
3. Feldmann M., Elliott M.J., Woody J.N., Maini R.N. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Adv Immunol 1997, 64:283-350.
4. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251.
5. Su C., Salzberg B.A., Lewis J.D., Deren J.J., Kornbluth A., Katzka D.A., et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97:2577.
6. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145.
7. ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206.
8. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A., Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774.
9. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
10. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
11. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
12. Sands B.E., Blank M.A., Patel K., van Deventer S.J. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2:912-920.
13. Rutgeerts P., Vermeire S., Van Assche G. Biological therapy for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-1197.
14. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:661-665.
15. Kuhner I. C-reactive protein and the acute-phase response. Hosp Pract 1990, 25(13, 16):21-28.
16. Tall A.R. C-reactive protein reassessed. N Engl J Med 2004, 350:1450-1452.
17. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toysα. Gut 2006, 55:426-431.
18. Vermeire S., Van Assche G., Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2:580-586.
19. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut Nov. 2008, 57(11):1518-1523.
20. Consigny Y., Modigliani R., Colombel J.F., Dupas J.L., Lémann M., Mary J.Y. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006, 12:551-557.
21. Boirivant M., Leoni M., Tariciotti D., Fais S., Squarcia O., Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988, 10:401-405.
22. Brignola C., Campieri M., Bazzocchi G., Farruggia P., Tragnone A., Lanfranchi G.A. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986, 91:1490-1494.
23. Oussalah A., Chevaux J.B., Fay R., Sandborn W.J., Bigard M.A., Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol May 2010, 105(5):1142-1149.
24. Bitton A., Dobkin P.L., Edwardes M.D., Sewitch M.J., Meddings J.B., Rawal S., et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 2008, 57:1386-1392.
25. Panaccione R., Fedorak R.N., Aumais G., Bernard E.J., Bernstein C.N., Bitton A., et al. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol Mar. 2008, 22(3):261-272.
26. Stange E.F., Travis S.P., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis Mar. 2008, 2(1):1-23.
27. Dignass A., Van Assche G., Lindsay J.O., Lémann M., Söderholm J., Colombel J.F., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis Feb. 2010, 4(1):28-62.
28. Vist G.E., Hagen K.B., Devereaux P.J., Bryant D., Kristoffersen D.T., Oxman A.D. Systematic review to determine whether participation in a trial influences outcome. BMJ May 21 2005, 330(7501):1175.
29. Reinisch W., Wang Y., Oddens B.J., Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012, 35:568-576.
30. Kiss L.S., Szamosi T., Molnar T., Miheller P., Lakatos L., Vincze A., et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther Oct. 2011, 34(8):911-922.
31. Rubin D.T., Mulani P., Chao J., Pollack P.F., Bensimon A.G., Yu A.P., et al. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis May 2012, 18(5):818-825.
32. Jürgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moerkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol May 2011, 9(5):421-427.
33. Louis E., Vermeire S., Rutgeerts P., De Vos M., Van Gossum A., Pescatore P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol Jul. 2002, 37(7):818-824.
34. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
35. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
36. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
37. Fagan E.A., Dyck R.F., Maton P.N., Hodgson H.J., Chadwick V.S., Petrie A., et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982 Aug, 12(4):351-359.
38. Koelewijn C.L., Schwartz M.P., Samsom M., Oldenburg B. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol Jan. 7 2008, 14(1):85-89.
39. Mould D.R., Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs Feb. 1 2010, 24(1):23-39.
40. Ordás I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther Apr. 2012, 91(4):635-646.
41. Fasanmade A.A., Adedokun O.J., Ford J., Hernandez D., Johanns J., Hu C., et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol Dec. 2009, 65(12):1211-1228.
42. Fasanmade A.A., Adedokun O.J., Blank M., Zhou H., Davis H.M. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther Jul. 2011, 33(7):946-964.
43. Seow C.H., Newman A., Irwin S.P., Steinhart A.H., Silverberg M.S., Greenberg G.R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut Jan. 2010, 59(1):49-54.
44. Sandborn W.J., Colombel J.F., D'Haens G., Plevy S.E., Panés J., Robinson A.M., et al. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin May 2013, 29(5):483-493.